S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in
NYSE:TDOC

Teladoc Health Competitors

$219.55
-34.98 (-13.74 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$216.81
Now: $219.55
$246.66
50-Day Range
$220.86
MA: $262.86
$294.54
52-Week Range
$102.01
Now: $219.55
$308.00
Volume9.02 million shs
Average Volume3.29 million shs
Market Capitalization$31.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.3

Competitors

Teladoc Health (NYSE:TDOC) Vs. SNY, SYK, ISRG, GSK, GILD, and ZTS

Should you be buying TDOC stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Teladoc Health, including Sanofi (SNY), Stryker (SYK), Intuitive Surgical (ISRG), GlaxoSmithKline (GSK), Gilead Sciences (GILD), and Zoetis (ZTS).

Sanofi (NASDAQ:SNY) and Teladoc Health (NYSE:TDOC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Earnings & Valuation

This table compares Sanofi and Teladoc Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanofi$40.00 billion2.87$3.26 billion$3.3213.80
Teladoc Health$553.31 million57.52$-98,860,000.00($1.49)-147.35

Sanofi has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

6.9% of Sanofi shares are owned by institutional investors. Comparatively, 51.8% of Teladoc Health shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 3.4% of Teladoc Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Sanofi and Teladoc Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sanofi14402.33
Teladoc Health0131702.57

Teladoc Health has a consensus price target of $242.5484, indicating a potential upside of 10.48%. Given Teladoc Health's stronger consensus rating and higher possible upside, analysts plainly believe Teladoc Health is more favorable than Sanofi.

Volatility and Risk

Sanofi has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Profitability

This table compares Sanofi and Teladoc Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sanofi14.49%24.77%13.28%
Teladoc Health-12.71%-6.15%-3.75%

Summary

Sanofi beats Teladoc Health on 8 of the 14 factors compared between the two stocks.

Stryker (NYSE:SYK) and Teladoc Health (NYSE:TDOC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Earnings & Valuation

This table compares Stryker and Teladoc Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion6.21$2.08 billion$8.2629.76
Teladoc Health$553.31 million57.52$-98,860,000.00($1.49)-147.35

Stryker has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

71.5% of Stryker shares are owned by institutional investors. Comparatively, 51.8% of Teladoc Health shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 3.4% of Teladoc Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Stryker and Teladoc Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker261412.61
Teladoc Health0131702.57

Stryker currently has a consensus price target of $231.00, indicating a potential downside of 6.01%. Teladoc Health has a consensus price target of $242.5484, indicating a potential upside of 10.48%. Given Teladoc Health's higher possible upside, analysts plainly believe Teladoc Health is more favorable than Stryker.

Volatility and Risk

Stryker has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Profitability

This table compares Stryker and Teladoc Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker12.35%20.94%8.77%
Teladoc Health-12.71%-6.15%-3.75%

Summary

Stryker beats Teladoc Health on 12 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and Teladoc Health (NYSE:TDOC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Earnings & Valuation

This table compares Intuitive Surgical and Teladoc Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion19.50$1.38 billion$9.9574.55
Teladoc Health$553.31 million57.52$-98,860,000.00($1.49)-147.35

Intuitive Surgical has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

86.5% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 51.8% of Teladoc Health shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by insiders. Comparatively, 3.4% of Teladoc Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Intuitive Surgical and Teladoc Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical381002.33
Teladoc Health0131702.57

Intuitive Surgical currently has a consensus price target of $736.75, indicating a potential downside of 0.68%. Teladoc Health has a consensus price target of $242.5484, indicating a potential upside of 10.48%. Given Teladoc Health's stronger consensus rating and higher possible upside, analysts plainly believe Teladoc Health is more favorable than Intuitive Surgical.

Volatility and Risk

Intuitive Surgical has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Profitability

This table compares Intuitive Surgical and Teladoc Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
Teladoc Health-12.71%-6.15%-3.75%

Summary

Intuitive Surgical beats Teladoc Health on 9 of the 14 factors compared between the two stocks.

GlaxoSmithKline (NYSE:GSK) and Teladoc Health (NYSE:TDOC) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for GlaxoSmithKline and Teladoc Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GlaxoSmithKline33602.25
Teladoc Health0131702.57

Teladoc Health has a consensus price target of $242.5484, indicating a potential upside of 10.48%. Given Teladoc Health's stronger consensus rating and higher possible upside, analysts plainly believe Teladoc Health is more favorable than GlaxoSmithKline.

Profitability

This table compares GlaxoSmithKline and Teladoc Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GlaxoSmithKline18.50%29.60%7.11%
Teladoc Health-12.71%-6.15%-3.75%

Institutional and Insider Ownership

11.8% of GlaxoSmithKline shares are owned by institutional investors. Comparatively, 51.8% of Teladoc Health shares are owned by institutional investors. 10.0% of GlaxoSmithKline shares are owned by insiders. Comparatively, 3.4% of Teladoc Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares GlaxoSmithKline and Teladoc Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlaxoSmithKline$43.10 billion2.00$5.93 billion$3.1710.85
Teladoc Health$553.31 million57.52$-98,860,000.00($1.49)-147.35

GlaxoSmithKline has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than GlaxoSmithKline, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

GlaxoSmithKline has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Summary

GlaxoSmithKline beats Teladoc Health on 9 of the 14 factors compared between the two stocks.

Teladoc Health (NYSE:TDOC) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Teladoc Health and Gilead Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teladoc Health0131702.57
Gilead Sciences2121202.38

Teladoc Health currently has a consensus target price of $242.5484, indicating a potential upside of 10.48%. Gilead Sciences has a consensus target price of $96.0370, indicating a potential upside of 52.95%. Given Gilead Sciences' higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Teladoc Health.

Profitability

This table compares Teladoc Health and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teladoc Health-12.71%-6.15%-3.75%
Gilead Sciences5.48%37.77%12.76%

Institutional and Insider Ownership

51.8% of Teladoc Health shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 3.4% of Teladoc Health shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Teladoc Health and Gilead Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teladoc Health$553.31 million57.52$-98,860,000.00($1.49)-147.35
Gilead Sciences$22.45 billion3.51$5.39 billion$6.1410.23

Gilead Sciences has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Teladoc Health has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Summary

Gilead Sciences beats Teladoc Health on 10 of the 14 factors compared between the two stocks.

Teladoc Health (NYSE:TDOC) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Teladoc Health and Zoetis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teladoc Health0131702.57
Zoetis07802.53

Teladoc Health currently has a consensus target price of $242.5484, indicating a potential upside of 10.48%. Zoetis has a consensus target price of $167.25, indicating a potential upside of 6.88%. Given Teladoc Health's stronger consensus rating and higher probable upside, analysts clearly believe Teladoc Health is more favorable than Zoetis.

Profitability

This table compares Teladoc Health and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teladoc Health-12.71%-6.15%-3.75%
Zoetis25.50%63.89%14.99%

Institutional and Insider Ownership

51.8% of Teladoc Health shares are owned by institutional investors. Comparatively, 92.5% of Zoetis shares are owned by institutional investors. 3.4% of Teladoc Health shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Teladoc Health and Zoetis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teladoc Health$553.31 million57.52$-98,860,000.00($1.49)-147.35
Zoetis$6.26 billion11.88$1.50 billion$3.6442.99

Zoetis has higher revenue and earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Teladoc Health has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.

Summary

Zoetis beats Teladoc Health on 9 of the 14 factors compared between the two stocks.


Teladoc Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SNY
Sanofi
1.6$45.80-1.8%$114.69 billion$40.00 billion19.57
Stryker logo
SYK
Stryker
2.0$245.78-1.2%$92.46 billion$14.88 billion53.31Analyst Report
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$741.79-2.3%$87.32 billion$4.48 billion84.49
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.1$34.38-0.9%$86.24 billion$43.10 billion10.58
Gilead Sciences logo
GILD
Gilead Sciences
2.7$62.79-1.5%$78.71 billion$22.45 billion64.73
Zoetis logo
ZTS
Zoetis
2.1$156.48-1.6%$74.35 billion$6.26 billion46.43Insider Buying
Anthem logo
ANTM
Anthem
2.6$300.24-1.8%$73.53 billion$104.21 billion15.52
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.4$247.15-0.2%$71.81 billion$17.12 billion90.53
Illumina logo
ILMN
Illumina
1.7$445.86-3.4%$65.05 billion$3.54 billion103.45
HCA Healthcare logo
HCA
HCA Healthcare
2.3$175.03-0.2%$59.50 billion$51.34 billion17.70Insider Selling
MRNA
Moderna
1.6$148.38-2.4%$58.72 billion$60.21 million-91.59Earnings Announcement
Analyst Report
Insider Selling
Gap Down
Boston Scientific logo
BSX
Boston Scientific
2.0$39.67-0.4%$56.80 billion$10.74 billion15.20Insider Selling
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$212.98-1.9%$55.37 billion$4.16 billion26.89Analyst Upgrade
TAK
Takeda Pharmaceutical
2.0$16.75-2.8%$52.81 billion$30.20 billion55.84
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.6$83.97-0.6%$52.44 billion$4.35 billion67.18Insider Selling
Humana logo
HUM
Humana
2.3$380.59-0.2%$49.04 billion$64.89 billion12.20Insider Selling
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$453.19-1.2%$48.55 billion$7.86 billion16.56Analyst Report
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$518.28-2.8%$44.27 billion$2.41 billion90.29Insider Selling
Align Technology logo
ALGN
Align Technology
2.0$556.11-3.1%$43.85 billion$2.41 billion25.30Insider Selling
Biogen logo
BIIB
Biogen
1.9$277.26-2.0%$42.24 billion$14.38 billion9.18
Baxter International logo
BAX
Baxter International
2.3$78.65-0.5%$39.73 billion$11.36 billion44.69
DexCom logo
DXCM
DexCom
1.7$395.47-2.6%$38.04 billion$1.48 billion163.42Insider Selling
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.1$164.50-0.5%$34.19 billion$7.98 billion1,028.19
Centene logo
CNC
Centene
2.1$58.76-1.0%$34.17 billion$74.64 billion16.37
ALC
Alcon
1.2$69.97-0.1%$34.16 billion$7.51 billion-47.60Earnings Announcement
Analyst Downgrade
Gap Down
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$153.65-0.5%$33.78 billion$4.99 billion35.90
BeiGene logo
BGNE
BeiGene
1.1$329.73-1.6%$30.16 billion$428.21 million-16.32Upcoming Earnings
Analyst Report
News Coverage
ResMed logo
RMD
ResMed
1.4$194.98-3.1%$28.37 billion$2.96 billion41.84
McKesson logo
MCK
McKesson
2.2$174.11-4.1%$27.71 billion$231.05 billion13.25
Seagen logo
SGEN
Seagen
1.7$150.09-3.3%$27.19 billion$916.71 million59.09
BNTX
BioNTech
0.9$112.33-1.6%$27.05 billion$121.63 million-56.17
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.6$236.53-3.4%$23.04 billion$11.55 billion27.54
Exact Sciences logo
EXAS
Exact Sciences
1.8$131.30-2.7%$22.20 billion$876.29 million-59.41Analyst Downgrade
Insider Selling
News Coverage
GMAB
Genmab A/S
1.7$33.68-4.3%$22.08 billion$804.57 million26.11Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Cerner logo
CERN
Cerner
2.9$69.94-0.5%$21.42 billion$5.69 billion27.32Insider Buying
AmerisourceBergen logo
ABC
AmerisourceBergen
2.1$102.85-2.3%$21.05 billion$189.89 billion-6.13
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
2.1$277.68-0.4%$20.53 billion$1.84 billion73.27Analyst Upgrade
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.9$35.03-0.9%$20.52 billion$19.58 billion13.90Analyst Downgrade
Analyst Revision
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$90.57-5.4%$19.99 billion$1.30 billion24.75Earnings Announcement
Insider Selling
The Cooper Companies logo
COO
The Cooper Companies
1.7$392.13-0.1%$19.27 billion$2.43 billion81.52Upcoming Earnings
Analyst Report
Catalent logo
CTLT
Catalent
1.5$112.25-2.6%$19.11 billion$3.09 billion71.50
Teleflex logo
TFX
Teleflex
2.0$402.48-0.5%$18.74 billion$2.60 billion51.80Earnings Announcement
Dividend Announcement
Analyst Report
Hologic logo
HOLX
Hologic
2.1$72.36-3.9%$18.64 billion$3.78 billion17.23
BIO.B
Bio-Rad Laboratories
0.7$600.70-0.0%$17.92 billion$2.31 billion5.14
GDRX
GoodRx
1.2$45.55-4.5%$17.78 billion$388.22 million0.00
Smith & Nephew logo
SNN
Smith & Nephew
2.0$39.64-3.0%$17.38 billion$5.14 billion19.43Dividend Increase
Analyst Report
High Trading Volume
CureVac logo
CVAC
CureVac
0.6$92.97-5.6%$17.38 billionN/A0.00
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$582.45-2.1%$17.38 billion$2.31 billion4.99
TXG
10x Genomics
1.6$173.10-3.7%$17.37 billion$245.89 million-128.22Analyst Downgrade
News Coverage
Insulet logo
PODD
Insulet
1.3$262.67-0.1%$17.32 billion$738.20 million596.99Earnings Announcement
Analyst Report
Analyst Revision
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.